| Primary | Change in Body Weight (%) | Percentage change in body weight from baseline (week 0) to end of treatment (week 44) is presented. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Percentage change in body weight | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG000-12.2± 8.2
- OG001-2.2± 5.4
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| Treatment policy estimand | ANCOVA | | <0.0001 | | Treatment difference | -9.87 | | | 2-Sided | 95 | -11.78 | -7.96 | | | | | Superiority | Week 44 responses were analysed using an analysis of covariance model with randomised treatment and type 2 diabetes status at screening as factors and baseline body weight as covariate. | |
|
| Primary | Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No) | Number of participants who achieved ≥5% body weight reduction at the end of treatment (week 44) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 5% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 5% weight reduction. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Count of Participants | | Participants | | At end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44. |
| |
| Secondary | Number of Participants Who Achieved Body Weight Reduction ≥ 10% (Yes/No) | Number of participants who achieved ≥10% body weight reduction at the end of treatment (week 44) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 10% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 10% weight reduction. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Count of Participants | | Participants | | At end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in Waist Circumference | Change in waist circumference from baseline (week 0) to end of treatment (week 44) is presented. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Centimeter (cm) | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in Body Weight (kg) | Change in body weight in kilogram (kg) from baseline (week 0) to end of treatment (week 44) is presented. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Kg | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in Body Mass Index | Change in body mass index from baseline (week 0) to end of treatment (week 44) is presented. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Kilogram per square meter (kg/m^2) | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in Waist-height Ratio (WtHR) | Change in waist-height ratio (WtHR) from baseline (week 0) to end of treatment (week 44) is presented. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Ratio of waist-height | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in Systolic Blood Pressure | Change in systolic blood pressure from baseline (week 0) to end of treatment (week 44) is presented. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Millimeter of mercury (mmHg) | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in Diastolic Blood Pressure | Change in diastolic blood pressure from baseline (week 0) to end of treatment (week 44) is presented | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mmHg | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in Total Cholesterol (mmol/L) - Ratio to Baseline | Change in total cholesterol measured in millimoles per liter (mmol/L) from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Ratio of total cholesterol | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in High Density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline | Change in high density lipoprotein (HDL) cholesterol measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Ratio of HDL | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in Low Density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline | Change in low density lipoprotein (LDL) cholesterol measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Ratio of LDL | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in Very Low-Density Lipoproteins (VLDL) Cholesterol (mmol/L) - Ratio to Baseline | Change in VLDL cholesterol measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Ratio of VLDL | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in Triglycerides (mmol/L) - Ratio to Baseline | Change in triglycerides measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Ratio of triglycerides | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in Free Fatty Acids (mmol/L) - Ratio to Baseline | Change in free fatty acids measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Ratio of free fatty acids | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline | Change in high sensitivity C-Reactive Protein (hsCRP) measured in milligram per litre (mg/L) from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Ratio of hsCRP | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in HbA1c (%) | Change in glycosylated haemoglobin (HbA1c) in percentage from baseline (week 0) to end of treatment (week 44) is presented. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Percentage of HbA1c | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in HbA1c (mmol/Mol) | Change in HbA1c measured in millimoles per mole (mmol/mol) from baseline (week 0) to end of treatment (week 44) is presented. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mmol/mol | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in Fasting Plasma Glucose (mg/dL) | Change in fasting plasma glucose (FPG) measured in milligrams per deciliter (mg/dL) from baseline (week 0) to end of treatment (week 44) is presented. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mg/dL | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in Fasting Plasma Glucose (mmol/L) | Change in FPG measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented. | FAS included all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mmol/L | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Number of Treatment Emergent Adverse Events (TEAEs) | Number of TEAEs from baseline (week 0) to end of study (week 49) is presented. An adverse event is any untoward medical occurrence in a clinical trial participant that is temporally associated with the use of an investigational medicinal product (IMP), whether or not considered related to the IMP. | Safety analysis set (SAS) included all participants who were exposed to at least one dose of randomised IMP. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Number | | Events | | From baseline (week 0) to end of study (week 49) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Number of Serious Adverse Events (SAEs) | Number of SAEs from baseline (week 0) to end of study (week 49) is presented. A serious adverse event (SAE) is any untoward medical occurrence that fulfils at least one of following criteria: results in death; is life-threatening; requires inpatient or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect; important medical event. | SAS included all participants who were exposed to at least one dose of randomised IMP. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Number | | Events | | From baseline (week 0) to end of study (week 49) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Change in Pulse | Change in pulse from baseline (week 0) to end of treatment (week 44) is presented. | SAS included all participants who were exposed to at least one dose of randomised IMP. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Beats per minute (Beats/min) | | Baseline (week 0), end of treatment (week 44) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |
| Secondary | Number of Clinically Significant Hypoglycaemic Episodes (Level 2) Less Than (<) 3.0 mmol/L Confirmed by Blood Glucose (BG) Meter - Participants With Type 2 Diabetes (T2D) | Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol/L) confirmed by BG meter for participants with T2D from baseline (week 0) to end of study (week 49) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of less than 3.0 mmol/L (54 mg/dL) confirmed by BG meter. | SAS included all participants who were exposed to at least one dose of randomised IMP. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Number | | Episodes | | From baseline (week 0) to end of study (week 49) | | | | ID | Title | Description |
|---|
| OG000 | Semaglutide 2.4 mg | Participants received subcutaneous (s.c.) injection of semaglutide once weekly in a dose escalation manner. The dose was increased every 4 weeks up to week 16 (0.25, 0.5, 1.0, 1.7 and 2.4 mg) followed by maintenance dose of 2.4 mg up to week 44 adjunct to a reduced calorie diet and increased physical activity. | | OG001 | Placebo | Participants received placebo matched to semaglutide s.c. once weekly up to week 44 adjunct to a reduced calorie diet and increased physical activity. |
| |